P/E ratio for Pacific Biosciences (PACB)
P/E ratio as of April 2024 (TTM): -1.24
According to Pacific Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.24409. At the end of 2022 the company had a P/E ratio of -5.84.
P/E ratio history for Pacific Biosciences from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.84 | -74.58% |
| 2021 | -23.0 | -110.63% |
| 2020 | 216 | -2415.57% |
| 2019 | -9.34 | -2.86% |
| 2018 | -9.61 | 223.99% |
| 2017 | -2.97 | -35.21% |
| 2016 | -4.58 | -85.01% |
| 2015 | -30.5 | 266.11% |
| 2014 | -8.34 | 102.53% |
| 2013 | -4.12 | 311.81% |
| 2012 | -1.0000 | -27.5% |
| 2011 | -1.38 | 1118.57% |
| 2010 | -0.1132 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 37.3 | -3,099.61% | 🇺🇸 USA |
 General Electric GE | 18.6 | -1,598.93% | 🇺🇸 USA |
 Illumina ILMN | -4.68 | 276.41% | 🇺🇸 USA |
 PerkinElmer
PKI | 15.0 | -1,303.02% | 🇺🇸 USA |
 Luminex LMNX | N/A | N/A | 🇺🇸 USA |
 NanoString Technologies NSTG | -0.0297 | -97.61% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.